124 related articles for article (PubMed ID: 38061174)
1. The effect of cisplatin-based chemotherapy on hearing loss (the frequency of >8 kHz) in children with cancer.
Zand V; Mandegari M; Baradaranfar M; Vaziribozorg S; Shahzeidi A
Am J Otolaryngol; 2024; 45(2):104127. PubMed ID: 38061174
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
Frisina RD; Wheeler HE; Fossa SD; Kerns SL; Fung C; Sesso HD; Monahan PO; Feldman DR; Hamilton R; Vaughn DJ; Beard CJ; Budnick A; Johnson EM; Ardeshir-Rouhani-Fard S; Einhorn LH; Lipshultz SE; Dolan ME; Travis LB
J Clin Oncol; 2016 Aug; 34(23):2712-20. PubMed ID: 27354478
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
[TBL] [Abstract][Full Text] [Related]
4. Hearing loss in Mexican children treated with cisplatin.
Castelán-Martínez OD; Jiménez-Méndez R; Rodríguez-Islas F; Fierro-Evans M; Vázquez-Gómez BE; Medina-Sansón A; Clark P; Carleton B; Ross C; Hildebrand C; Castañeda-Hernández G; Rivas-Ruiz R
Int J Pediatr Otorhinolaryngol; 2014 Sep; 78(9):1456-60. PubMed ID: 25037447
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.
Stöhr W; Langer T; Kremers A; Bielack S; Lamprecht-Dinnesen A; Frey E; Beck JD;
Cancer Invest; 2005; 23(3):201-7. PubMed ID: 15945505
[TBL] [Abstract][Full Text] [Related]
6. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
Freyer DR; Chen L; Krailo MD; Knight K; Villaluna D; Bliss B; Pollock BH; Ramdas J; Lange B; Van Hoff D; VanSoelen ML; Wiernikowski J; Neuwelt EA; Sung L
Lancet Oncol; 2017 Jan; 18(1):63-74. PubMed ID: 27914822
[TBL] [Abstract][Full Text] [Related]
7. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].
Schmidt CM; Bartholomäus E; Deuster D; Heinecke A; Dinnesen AG
HNO; 2007 Apr; 55(4):299-306. PubMed ID: 16437215
[TBL] [Abstract][Full Text] [Related]
8. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
9. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.
Haugnes HS; Stenklev NC; Brydøy M; Dahl O; Wilsgaard T; Laukli E; Fosså SD
Acta Oncol; 2018 Aug; 57(8):1075-1083. PubMed ID: 29384420
[TBL] [Abstract][Full Text] [Related]
10. Applications of the Grading Scales for the Detection of Ototoxicity in Children after Treatment of Neuroblastoma and Extracranial Germinal Tumor.
Polski B; Sosnowska-Sienkiewicz P; Szydłowski J; Januszkiewicz-Lewandowska D
Audiol Neurootol; 2023; 28(1):32-42. PubMed ID: 36191558
[TBL] [Abstract][Full Text] [Related]
11. Platinum-induced hearing loss after treatment for childhood cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010181. PubMed ID: 27486906
[TBL] [Abstract][Full Text] [Related]
12. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
13. Risk factors associated with cisplatin-induced ototoxicity in Japanese patients with solid tumors.
Okada H; Kitagawa K
Cancer Med; 2023 Apr; 12(7):7904-7910. PubMed ID: 36567514
[TBL] [Abstract][Full Text] [Related]
14. [Hearing assessment of children treated with Cisplatin].
Mniszek J; Bielecki I; Sobol G
Pol Merkur Lekarski; 2009 Aug; 27(158):105-8. PubMed ID: 19856874
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a cisplatin dose-ototoxicity model.
Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
[TBL] [Abstract][Full Text] [Related]
16. Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens.
Kolinsky DC; Hayashi SS; Karzon R; Mao J; Hayashi RJ
J Pediatr Hematol Oncol; 2010 Mar; 32(2):119-23. PubMed ID: 20098336
[TBL] [Abstract][Full Text] [Related]
17. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy.
Weissenstein A; Deuster D; Knief A; Zehnhoff-Dinnesen AA; Schmidt CM
Int J Pediatr Otorhinolaryngol; 2012 Jan; 76(1):131-6. PubMed ID: 22104469
[TBL] [Abstract][Full Text] [Related]
18. Statistical model for prediction of hearing loss in patients receiving cisplatin chemotherapy.
Johnson A; Tarima S; Wong S; Friedland DR; Runge CL
JAMA Otolaryngol Head Neck Surg; 2013 Mar; 139(3):256-64. PubMed ID: 23429908
[TBL] [Abstract][Full Text] [Related]
19. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
20. Relationship between cisplatin administration and the development of ototoxicity.
Rademaker-Lakhai JM; Crul M; Zuur L; Baas P; Beijnen JH; Simis YJ; van Zandwijk N; Schellens JH
J Clin Oncol; 2006 Feb; 24(6):918-24. PubMed ID: 16484702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
